Breakthrough therapy status has been granted by the FDA to GlycoMimetics' GMI-1271 as a treatment for adult patients with relapsed/refractory acute myeloid leukemia. The company has an ongoing midstage trial to evaluate the combination treatment of GMI-1271 with chemotherapy in AML patients.
FDA grants breakthrough status to GlycoMimetics' leukemia drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.